Key result
The routine use of beta-blockers in patients with myocardial infarction and preserved left ventricular ejection fraction is being questioned in the era of modern therapeutics.
Why the study?
Does long-term treatment with beta-blockers improve outcomes in patients with myocardial infarction and a preserved left ventricular ejection fraction?
Does long-term treatment with beta-blockers improve outcomes in patients with myocardial infarction and a preserved left ventricular ejection fraction?
This editorial questions the routine use of long-term beta-blockers for secondary prevention in patients with myocardial infarction and preserved ejection fraction in the modern era.
Nearly half a century ago, trials were performed that provided convincing evidence that long-term treatment with beta-blockers can improve outcomes after a myocardial infarction. 1-3 These trials included a high proportion of patients with large myocardial infarctions who had a considerably worse prognosis than most patients who are seen today. These early trials were conducted before the advent of modern biomarker-based diagnosis of myocardial infarction, treatment strategies, and therapeutics. As a result, the use of beta-blockers in patients with myocardial infarction and a preserved left ventricular ejection fraction has been questioned — as evidenced by a series of studies that have . . .
No takes yet. Share an insight, caveat, or question.
Tomas Jernberg (2024) conducted an editorial in Myocardial infarction. Beta-blockers was evaluated. The routine use of beta-blockers in patients with myocardial infarction and preserved left ventricular ejection fraction is being questioned in the era of modern therapeutics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: